DanDrit Biotech USA Inc. Announces new Therapeutic Research Strategy
June 12, 2017
New York, USA
DanDrit Biotech USA, Inc. ("DanDrit" or the "Company") is pleased to announce that on June 6, 2017, Mr. Rene Sindlev and Mr. Torben BjÃ¸rn Christensen, joined Dandrit's Board of Directors (the "Board") as part of a new strategy to expand the Company's focus beyond its ongoing clinical drug trials to develop new therapeutic programs to treat cancer and other serious diseases.